Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06671314 · ClinicalTrials.gov registry record
Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
A clinical trial of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction, sponsored by Novartis.
- Completed
- Registry status
- 42,494
- Enrollment target
- 1
- Study location
NCT06671314 is a study of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction that has completed, run by Novartis. The registered enrollment target is 42,494 participants, above the 1,277-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (3228% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06671314, a study of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- 42,494 participants
- Enrollment target
- 1
- Study location
Study Summary
This was a retrospective observational cohort study using patient data from the Get With The Guideline-Heart Failure (GWTG-HF) registry linked to Medicare Fee-for-Service (FFS) claims. The main goal of the study was to compare home-time in Medicare FFS patients with heart failure with mildly reduced or preserved ejection fraction discharged with sacubitril/valsartan versus those discharged without sacubitril/valsartan.
Conditions Studied
Study Locations (1)
New Jersey
- Novartis Pharmaceuticals - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42,494 participants |
| Start Date | 2022-06-02 |
| Est. Completion | 2022-10-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06671314
The ClinicalTrials.gov registry entry for NCT06671314 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 42,494 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,277-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (3228% higher). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Heart Failure With Preserved Ejection Fraction appearing as the primary indexed condition, and to 0 interventions.
NCT06671314 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06671314 about?
NCT06671314 is a clinical study titled "Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction". This was a retrospective observational cohort study using patient data from the Get With The Guideline-Heart Failure (GWTG-HF) registry linked to Medicare Fee-for-Service (FFS) claims. The main goal of the study was to compare home-time in Medicare FFS patients with heart failure with mildly reduced...
What is the current status of trial NCT06671314?
This trial is currently completed. The enrollment target is 42,494 participants. The study started on 2022-06-02. Estimated completion is 2022-10-31.
What conditions does trial NCT06671314 study?
This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction.
Who is sponsoring clinical trial NCT06671314?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06671314 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure With Preserved Ejection Fraction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fiber Supplementation in Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · NA
-
Ketogenic Diet vs Mixed Diet in Patients With Heart Failure
RECRUITING · NA
-
Matching Perfusion and Metabolic Activity in HFpEF
RECRUITING · Phase 2
-
Pilot Study Lp299v Supplementation in Chronic Heart Failure
RECRUITING · NA
-
Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction
RECRUITING · Phase 3
-
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
RECRUITING · NA
Explore more on PlainTrial
Heart Failure With Preserved Ejection Fraction
All registered trials for this condition
Heart Failure With Reduced Ejection Fraction
All registered trials for this condition
New Jersey
All trials with a study site in New Jersey
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.